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Mutations of rpoB Gene in biofilm-embedded MRSA 395rpoB gene
Methods: The screening of rifampin-resistant MRSA isolates, from the biofilm at Day 5 with or
without exposure to the susceptible breakpoint concentration of rifampin recommended by
the Clinical and Laboratory Standards Institute (1 mg/L), was conducted using agar plates con-
taining rifampin. A partial fragment of RNA polymerase B subunit gene (rpoB), including clus-
ters I and II, was amplified and sequenced. The rifampin MIC values and mutation frequencies
at different sites of rpoB were measured and evaluated in rifampicin-resistant isolates.
Results: Rifampin-resistant mutants could be selected from all of 39 randomly selected
rifampin-susceptible MRSA isolates in the biofilm model. The spontaneous mutation frequency
ranged from 1.00  104 to 3.85  107. Mutation at codon 481 was most commonly found at 35
(89.7%) of 39 MRSA isolates. Without rifampin induction, the MIC ranged between 0.125 mg/L
and1024 mg/L and mutation sites included cluster I 464, 466, 468, 471, 474, 477, 481, 484, 486
and cluster II 519, 527, 529 with the percentage of 471 (35.9%), 477 (33.3%), 481 (53.8%), and
484 (35.9%). Conversely, with the induction of rifampin, the MIC value rangedw256e1024 mg/
L. The mutation sites that were more concentrated included 468 (17.9%), 477 (30.8%), 481
(89.7%), 484 (17.9%), and 486 (33.3%).
Conclusion: We documented high rifampin resistance induction activity when MRSA was
engaged in biofilm with rifampin exposure. Monotherapy seems to be inadequate for MRSA
in biofilm. There is an urgent need for developing effective combination therapies with less
rifampin resistance-inducing activities for treating MRSA in biofilms.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Biofilm-embedded methicillin-resistant Staphylococcus
aureus (MRSA) has been a common clinical problem, and
antimicrobial therapy has always been of limited success if
the infected prosthesis or foreign bodies were retained.1,2
The development of antibiotic combinations to improve
the antibacterial activity against the biofilm-embedded
microorganisms has been welcomed.3e5 One of the com-
mon combinations was the rifampin-containing regimen.
However, it is well known that rifampin-resistant isolates
with point mutations in RNA polymerase B subunit genes
(rpoB) were common with rifampin therapy for planktonic
MRSA, with a mutation frequency of w10L6e10L8.6e8 The
emergence and spread of rifampin-resistant MRSA during
vancomycinerifampin combination therapy in an intensive
care unit has been reported.9 The possibility of the emer-
gence of rifampin-resistant mutants with rpoB mutation
was high when rifampin was used as a component of com-
bination therapy to treat biofilm-embedded MRSA in-
fections.4,10,11 The clinical setting may further induce the
production of vancomycin-intermediate S. aureus.12,13
These research results highlighted the risk of treatment
failure with the combination of vancomycin and rifampin.
According to our recent study on rifampin-based com-
binations against biofilm-embedded MRSA, we found that
some combinations were prone to induce rifampin-resistant
mutants with high rifampin minimum inhibitory concen-
trations (MICs).11 The phenomenon was more obvious for
vancomycin-, teicoplanin-, or daptomycin-based combina-
tion regimens. However, the frequency of emergence of
rifampin-resistant mutants and genetic profiles among
biofilm-embedded MRSA is not clear. Therefore, we decided
to study some of the MRSA isolates from the program
Tigecycline In vitro Surveillance in Taiwan (TIST), and toinvestigate rifampin-resistant patterns and rpoB mutation
profiles among biofilm-embedded MRSA isolates.
Methods
Isolates
One hundred MRSA isolates causing a variety of clinical in-
fections, including central venous catheter, vascular graft,
orthopedic prostheses, or ventricular shunt infection, were
obtained from the TIST study at 22 hospitals from 2006 to
2010.14 Staphylococci were identified with colonial
morphology, Gram stain, and coagulase test. MRSA was
further confirmed by the tube coagulase test and growth on
6 mg/mL oxacillin salt agar screen plates. Isolates were
stored at 70C in Protect Bacterial Preservers (Technical
Service Consultants Limited, Heywood, UK) until use. From
78 rifampin-susceptible strains, 39 unique isolates were
randomly selected for further study, and their genetic
relatedness was excluded by pulse-field gel electrophoresis
as previously described.15,16
Antibiotics
The antibiotics tested included vancomycin, rifampin, and
minocycline (Sigma-Aldrich, St Louis, MO, USA), fosfomycin
(Ercros, Barcelona, Spain), linezolid and tigecycline (Pfizer,
New York, NY, USA), fusidic acid (Leo Pharma, Ballerup,
Denmark), teicoplanin (Sanofi-Aventis, Bridgewater, NJ,
USA), ciprofloxacin (Bayer, Leverkusen, Germany), and
daptomycin (Cubist Pharmaceuticals, Lexington, MA, USA).
The interpretation criteria for the susceptibility test and
the MIC determined by the agar dilution tests were based
on the recommendations of the Clinical and Laboratory
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Chemotherapy.17e19 For the fosfomycin susceptibility test,
glucose-6-phosphate (25 mg/mL) was added to the agar
plate. The daptomycin susceptibility test was performed in
Mu¨ellereHinton broth (Oxoid Microbiology Products,
Basingstoke, UK) adjusted to 50 mg/mL of calcium as per
the standard methodology. Mu¨ellereHinton agar (Oxoid
Microbiology Products) was used for MIC determination of S.
aureus. Inocula were prepared by suspending growth from
overnight cultures in saline to a turbidity of a 0.5 McFarland
standard. Inoculated plates were then incubated in
ambient air at 37C for 24 hours. S. aureus ATCC 29213 was
included as the control strain in each run of MIC
measurements.
Killing effects of antimicrobial agents in the
biofilms
Biofilms of individual strains were prepared in 24-well cul-
ture plates, according to a previously described method.14
The medium in the well was removed by aspiration, and
the biofilm was treated using rifampin alone. The concen-
trations of rifampin were adjusted to the susceptible
breakpoint concentration (SBC) recommended by the Clin-
ical and Laboratory Standards Institute12 (1 mg/mL). The
drug-containing medium was gently aspirated after 24
hours at 37C. The biofilm on the wells was incubated with
fresh drug dilution for 5 consecutive days and sonicated by
a water-table sonicator for 5 minutes. The disrupted biofilm
was serially diluted and plated for viable cell counting at
37C following overnight culture. The detection limit of the
plating count was 100 CFU/mL. All tests were performed in
triplicate for each experiment to ensure reproducibility.
Determination of spontaneous mutation frequency
for rifampin resistance
The screening of resistant strains from the biofilm at Day 5
was performed on agar plates containing 0 mg/mL, 0.05 mg/
mL, 2 mg/mL, 8 mg/mL, or 64 mg/mL rifampin. In all cases, a
sample of 100 mL from the sonicator-disrupted biofilm was
serially diluted and plated for viable cell counting at 37C
following overnight culture. After 24e36 hours, six colonies
growing on selective plates with rifampin (0.05 mg/mL) and
nonselective plates (plates without rifampin) were
selected. The MICs, mutation rates, and mutation fre-
quencies were calculated. Mutation rate was defined as the
percentage of mutation isolates among the 39 isolates and
calculated as the isolates number with mutation colonies
divided by 39. Mutation frequency was defined as the col-
ony counts from plates with different rifampin concentra-
tions divided by the colony counts from the plate without
rifampin. Silent mutation was defined as the nucleotide
change without the corresponding amino acid substitute.
rpoB mutation detection and DNA sequencing
Genomic DNA from MRSA was purified and used as a tem-
plate for polymerase chain reaction (PCR) amplification. In
the present study, a 460-bp rpoB fragment, including clus-
ters I and II of rpoB, was amplified and sequenced byprimers rpoB1 and rpoB2 as described previously.20 The DNA
sequences of the region of 1318e1602 at the nucleotide
positions (nt) of rpoB, corresponding to codons 440e534
[amino acid (aa) number], which includes the RFP
resistance-determining cluster I (1384e1464 nt, 462e488
aa) and cluster II (1543e1590 nt, 515e530 aa) of S. aureus,
were amplified by PCR with the primers rpoB-F (50-CCG TCG
TTT ACG TTC TGT AGG-30) and rpoB-R (50-AAA GCC GAA TTC
ATT TAC ACG-30). The PCR products were sequenced with
the same primers by the dideoxy chain termination method
in an ABI Prism 3130xl Genetic Analyzer (Applied Bio-
systems, Foster City, CA, USA).
Statistical analysis
Data analyses were performed using SPSS for Windows 17.0
(SPSS Inc., Chicago, IL, USA). Because of the small sample
size and the violation of the normal distribution assumption
of optical density ratios, ManneWhitney U test was used to
compare the differences between the two groups. Krus-
kaleWallis H test and Dunn’s test were applied for multiple
comparisons. Statistical significance was set to a p < 0.05.
Results
Among the 100 MRSA isolates from the TIST, MIC50/90 (mg/
mL) is listed in Table 1 and 78 isolates were susceptible to
rifampin. All 39 randomly selected rifampin-susceptible
MRSA isolates (MIC  0.03 mg/mL) yielded rifampin-
resistant mutants in the biofilm model. The spontaneous
rifampin mutation frequency (MIC  0.05 mg/mL) for the 39
MRSA isolates ranged from 1.00  10L4 to 3.85  10L7, with
a mean mutation frequency of 2.49  10L5 (Figure 1).
The results for the 39 MRSA isolates in the biofilm after
they had been exposed to 1 mg/mL of rifampin (SBC) for 5
days, including the bacterial loads (log10 CFU/mL) in the
control plate without rifampin and plates containing
0.05 mg/mL, 2 mg/mL, 8 mg/mL, or 64 mg/mL of rifampin,
can be seen in Figure 2. The mutation rate was 100%, and
the mutation frequency was 1 after the rifampin treat-
ment, and all of the mutation isolates had high rifampin
MICs (> 64 mg/mL).
We also checked the rifampin MICs of the biofilm-
embedded MRSA mutants cocultivated with rifampin
(1 mg/mL) for 5 days, which grew on 0.05 mg/mL and the
rpoB sequences. The mutation sites in rpoB and the MIC
changes in the 39 MRSA isolates embedded in the biofilm
are shown in Table 2. Codons 468, 477, 481, 484, and 486
were common hot spots. Among the 39 MRSA isolates, all
the isolates had at least one mutation site. Only one isolate
(TIST 97) had two concomitant codon mutations over 468
and 482. Nine isolates had only one codon change: 481
HiseTyr (CATeTAT, 8 isolates) and 477 AlaeAsp (GCTeGAT,
1). Twenty isolates had two codon changes, and eight iso-
lates had three codon changes. Only one isolate possessed
four mutation sites. A mutation at codon 481 was the most
common and was found in 35 (89.7%) isolates, of which 31
(79.5%) had 481 HiseTyr (CATeTAT). All 39 parent strains
had low MICs (ranging between 0.015 mg/mL and 0.03 mg/
mL), but all of the mutants had high MICs, >256 mg/mL (>
1024 mg/mL in 35 strains).
Table 1 The MIC of rifampin susceptible and non-
susceptible methicillin-resistant Staphylococcus aureus
isolates from Tigecycline In vitro Surveillance in Taiwan
(TIST).
RIF non-susceptible
N Z 22 MIC range MIC50 MIC90 S (%) I (%) R (%)
VA 1e2 2 2 100 0 0
TGC 0.25e1 0.5 0.5 90.9 d 9.1
MNO 0.125e8 0.25 8 77.3 22.7 0
TEC 0.5e2 2 2 100 0 0
FA 0.25e>64 0.25 8 86.4 d 13.6
LNZ 2e8 4 4 95.5 d 4.5
CIP 1e>64 >64 >64 9.1 90.9
RIF 2e>32 4 >32 0 45.5 54.5
FOS 1e>1024 >1024 >1024 45.5 0 54.5
DAP 0.125e1 0.5 1 100 d 0
RIF susceptible
N Z 78 MIC range MIC50 MIC90 S (%) I (%) R (%)
VA 1e2 2 2 100 0 0
TGC 0.25e2 0.5 0.5 91 d 9
MNO 0.125e8 0.25 8 76.9 23.1 0
TEC 0.5e2 1 2 100 0 0
FA 0.25e>64 0.25 8 84.6 d 15.4
LNZ 2e8 4 4 94.9 d 5.1
CIP 0.25e>64 1 >64 56.4 2.6 41
RIF 0.016e0.5 0.016 0.03 100 0 0
FOS 1e>1024 4 16 98.7 0 1.3
DAP 0.25e1 0.25 0.5 100 d 0
CIP Z ciprofloxacin; DAP Z daptomycin; FA Z fusidic acid;
FOS, fosfomycin; LNZ Z linezolid; MIC Z minimum inhibitory
concentration; MNO Z minocycline; RIF Z rifampicin;
TEC Z teicoplanin; TGC Z tigecycline; VA, vancomycin; S Z
Susceptible; I Z Intermediate; R Z Resistant.
Mutations of rpoB Gene in biofilm-embedded MRSA 397The sequence analyses of rpoB in the rifampin-
resistant mutants derived from the 39 biofilm-
embedded MRSA isolates are shown in Tables 2 and 3.
All amino acid substitutions were found in cluster I.
His481Tyr/Leu/Asp substitution was noted in 33 (84.6%)
isolates (MIC, 256e1024 mg/mL), Ser486Leu in 13 isolates
(33.3%; MIC, 512 mg/mL), Ala477Asp in 12 isolates (30.8%;
MIC, 512 mg/mL), Gln468Lys/Leu/Arg in eight isolates
(20.5%; MIC, 512e1024 mg/mL), and Arg484His in seven
isolates (17.9%; MIC, 512 mg/mL). An MRSA isolate could
have one to four amino acid substitutions, and an amino
acid position, such as codon 481, could have one of three
substitutes.
We also analyzed the mutation percentages of the rpoB
mutation sites of the 39 MRSA isolates with or without
rifampin in the biofilm and MICs (Table 3). Without
rifampin induction, the MIC ranged between 0.125 mg/mL
and 1024 mg/mL. The mutation sites included codons 464,
466, 468, 471, 474, 477, 481, 484, or 486 of cluster I and
519, 527, or 529 of cluster II. Among them, the percentage
of different mutation sites included 471 aa-14 isolates
(35.9%), 477 aa-12 isolates (30.8%), 481 aa-17 isolates
(43.6%), and 484 aa-13 isolates (33.3%). Conversely, with
rifampin induction, the MIC after mutation ranged be-
tween 256 mg/mL and 1024 mg/mL. The mutation sitesinduced by rifampin were more concentrated, including
codon 468 aa-8 isolates (20.5%), 477 aa-12 isolates (30.8%),
481 aa-33 isolates (84.6%), 484 aa-7 isolates (17.9%), and
486 aa-13 isolates (33.3%). By contrast, a silent mutation
site at 474 (AACeAAT) was found in 24 (61.5%) of the 39
MRSA isolates.Discussion
The study by Raad et al4 showed that rifampin could
initially cause a significant decline in the MRSA bacterial
load in biofilm. However, after repeated daily exposure to
rifampin, most of the MRSA isolates developed resistance to
this antibiotic.4 According to our previous study, the
rifampin MICs of biofilm-embedded MRSA isolates signifi-
cantly increased from 0.015 mg/mL to  4 mg/mL after 5
days of rifampin monotherapy at the SBC. By contrast,
fosfomycin exposure did not lead to evident MIC changes in
a similar setting.10
In vivo rifampin-resistant isolates emerging during
combination therapy of rifampin and vancomycin have
been previously reported.21 However, the combination of
vancomycin plus rifampin proved to be effective in resis-
tance prevention in an animal model of MRSA foreign body
osteomyelitis.22 Although the results were diverse from
different studies, we believe that such a combination may
easily induce rifampin resistance, especially for biofilm-
embedded MRSA.11 In our MRSA biofilm study, we found a
rapid increase in the rifampin MICs from < 0.06 mg/mL to >
64 mg/mL during rifampin monotherapy, as well as when
vancomycin, teicoplanin, or daptomycin were combined
with rifampin.11 High-level rifampin-resistant isolates (>
64 mg/mL) were commonly found among the above-
mentioned combinations.
The average frequency of rifampin mutation of S. aureus
without rifampin exposure was reported to be 3.2  10L9,6
and rifampin-resistant mutants emerged at a frequency of
w10L8 if induced by rifampin therapy.7 Another study re-
ported a mutation frequency of 10L6e10L8 in planktonic
MRSA isolates after exposure to rifampin at the concen-
tration of 1/2 MIC for 10 consecutive days.8 However, in our
study the frequency of spontaneous mutation in the 39
biofilm-embedded clinical MRSA isolates without rifampin
exposure, 2.49  10L5, was 100e100,000 times higher than
in the planktonic MRSA, highlighting the resistance-prone
microenvironment of biofilm formation.
Amino acid residues 468, 477, 481, and 486 have been
reported to be the common mutation sites in rifampin-
resistant MRSA isolates,15,22e24 in accordance with our re-
sults. The mutation sites of high-level rifampin-resistant
isolates (MIC > 128 mg/mL) were located in the published
hot spots, including the Gln468Lys, Ala477Asp, His481Tyr, or
Ser486Leu substitutions.13 However, amino acid sub-
stitutions at Ala47324 were not found in our MRSA isolates.
There were no mutations in the rifampin resistance-
determining cluster II (515e530 aa) among the rifampin
selected mutants. A collection of additional MRSA isolates
from other hospitals will be available for rpoB sequencing
among the rifampin-resistant isolates in the future.
Our mutation sites in the biofilm-embedded MRSA iso-
lates without rifampin exposure were similar to those
Figure 1. Bacterial load (log10 CFU/mL) of 39 methicillin-resistant Staphylococcus aureus isolates in the biofilm after 5 days
without exposure to any antibiotics. The colony grew in control (black bar) and rifampicin 0.05 mg/mL containing medium (white
bar). Mean mutation frequency, 2.49  105; mutation frequency range from 1.00  104 to 3.85  107.
Figure 2. Bacterial load (log10 CFU/mL) of 39 methicillin-resistant Staphylococcus aureus isolates in the biofilm after 5 days of
exposure to rifampicin 1 (mg/mL; susceptible breakpoint concentration). The colony grew in control (black bar) and rifampicin
0.05 mg/mL (red bar), 2 mg/mL (green bar), 8 mg/mL (yellow bar), and 64 mg/mL (blue bar) containing medium. Mean mutation rate
was w100% after the rifampicin treatment.
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Table 2 Mutation sites of rpoB and minimum inhibitory concentrations (MICs) of 39 methicillin-resistant Staphylococcus
aureus isolates in the biofilm cocultivated with rifampicin (1 mg/L) for 5 days.






T-2 481 His/Tyr(CAT/TAT)/481 His/Leu(CAT/CTT) 1.5  108 0.015 1024/256
T-3 481 His/Tyr(CAT/TAT) 3.2  107 0.015 1024
T-5 477 Ala/Asp(GCT/GAT) 5.5  107 0.015 512
T-8 481 His/Tyr(CAT/TAT)/486 Ser/Leu(TCA/TTA) 1.4  108 0.03 1024/512
T-10 481 His/Tyr(CAT/TAT) 6.2  107 0.015 1024
T-13 468 Gln/Leu(CAA/CTA)/481 His/Tyr(CAT/TAT)/
484 Arg/His(CGT/CAT)
2.6  108 0.03 512/1024/512
T-14 481 His/Tyr(CAT/TAT)/484 Arg/His(CGT/CAT)/
486 Ser/Leu(TCA/TTA)
3.1  108 0.03 1024/512/512
T-17 481 His/Tyr(CAT/TAT)/486 Ser/Leu(TCA/TTA) 5.2  108 0.015 1024/512
T-18 481 His/Tyr(CAT/TAT) 7.5  107 0.015 1024
T-19 481 His/Tyr(CAT/TAT)/481 His/Asp(CAT/GAT) 1.4  108 0.03 1024/1024
T-22 481 His/Tyr(CAT/TAT)/484 Arg/His(CGT/CAT) 2.3  107 0.015 1024/512
T-23 477 Ala/Asp(GCT/GAT)/481 His/Tyr(CAT/TAT) 1.3  107 0.015 512/1024
T-29 477 Ala/Asp(GCT/GAT)/481 His/Asp(CAT/GAT) 1.0  108 0.03 512/1024
T-31 481 His/Tyr(CAT/TAT) 4.0  108 0.03 1024
T-35 481 His/Tyr(CAT/TAT) 3.0  108 0.015 1024
T-36 468 Gln/Leu(CAA/CTA)/481 His/Tyr(CAT/TAT) 2.0  108 0.015 512/1024
T-41 477 Ala/Asp(GCT/GAT)/481 His/Tyr(CAT/TAT) 1.3  107 0.015 512/1024
T-42 477 Ala/Asp(GCT/GAT)/481 His/Tyr(CAT/TAT)/
486 Ser/Leu(TCA/TTA)
8.0  107 0.015 512/1024/512
T-45 481 His/Tyr(CAT/TAT)/481 His/Asp(CAT/GAT) 2.6  108 0.015 1024/1024
T-46 481 His/Tyr(CAT/TAT)/484 Arg/His(CGT/CAT)/
486 Ser/Leu(TCA/TTA)
2.6  107 0.015 1024/512/512
T-49 468 Gln/Lys(CAA/AAA)/477 Ala/Asp(GCT/GAT) 1.2  108 0.015 1024/512
T-50 481 His/Tyr(CAT/TAT)/486 Ser/Leu(TCA/TTA) 4.9  107 0.015 1024/512
T-53 481 His/Tyr(CAT/TAT)/486 Ser/Leu(TCA/TTA) 4.0  107 0.015 1024/512
T-55 481 His/Tyr(CAT/TAT)/481His/Leu(CAT/CTT)/
484 Arg/His(CGT/CAT)
1.5  107 0.015 1024/512/512
T-59 477 Ala/Asp(GCT/GAT)/481 His/Tyr(CAT/TAT)/
481 His/Leu(CAT/CTT)/486 Ser/Leu(TCA/TTA)
3.0  107 0.015 512/1024/256/512
T-62 468 Gln/Leu(CAA/CTA)/477 Ala/Asp(GCT/GAT)/
486 Ser/Leu(TCA/TTA)
8.0  107 0.015 512/512/512
T-63 468 Gln/Lys(CAA/AAA)/481 His/Tyr(CAT/TAT) 1.4  108 0.015 1024/1024
T-65 481 His/Tyr(CAT/TAT)/484 Arg/His(CGT/CAT) 1.2  107 0.015 1024/512
T-69 468 Gln/Lys(CAA/AAA)/484 Arg/His(CGT/CAT) 5.5  105 0.015 1024/512
T-70 477 Ala/Asp(GCT/GAT)/486 Ser/Leu(TCA/TTA) 2.2  107 0.015 512/512
T-74 477 Ala/Asp(GCT/GAT)/481 His/Tyr(CAT/TAT)/
481 His/Leu(CAT/CTT)
5.3  106 0.015 512/1024/256
T-75 481 His/Tyr(CAT/TAT) 1.6  107 0.015 1024
T-77 481 His/Tyr(CAT/TAT) 2.0  106 0.015 1024
T-80 477 Ala/Asp(GCT/GAT)/481 His/Tyr(CAT/TAT) 4.2  106 0.015 512/1024
T-83 481 His/Tyr(CAT/TAT) 3.0  106 0.015 1024
T-86 468 Gln/Lys(CAA/AAA)/486 Ser/Leu(TCA/TTA) 1.7  108 0.015 1024/512
T-88 477 Ala/Asp(GCT/GAT)/481 His/Tyr(CAT/TAT)/
486 Ser/Leu(TCA/TTA)
1.9  107 0.015 512/1024/512
T-97 468/482 Gln/Leu/Lys/Asp(CAA/CTA/AAA/AAT)/
481 His/Asp(CAT/GAT)
1.5  108 0.015 1024/1024
T-100 468 Gln/Arg(TCA/TTA)/486 Ser/Leu(TCA/TTA) 2.0  108 0.015 512/512
Mutations of rpoB Gene in biofilm-embedded MRSA 399reported in the literature.23 However, the mutation sites of
the rifampin-treated biofilm-embedded isolates were
limited to codons 468, 477, 481, 484, and 486, which was
more “localized” than those of biofilm-embedded isolateswithout rifampin exposure. The MICs of the rifampin-
treated biofilm-embedded MRSA isolates were always
higher than those of the biofilm-embedded MRSA isolates
without rifampin exposure, indicating that there is a
Table 3 Mutation percentages for different mutation sites, minimum inhibitory concentrations (MICs), and mutation sites in
the rpoB gene of 39 methicillin-resistant Staphylococcus aureus isolates with or without rifampicin in biofilm.
Biofilm without rifampin Biofilm with rifampin
Mutation site Mutation
N (%)





Ser/Pro(TCT/CCT) 2 (5.1) 256
466 1 (2.6)
Leu/Ser(TTA/TCA) 1 (2.6) <1
468 8 (20.5) 468 8 (20.5)
Gln/Lys(CAA/AAA) 4 (10.3) 1024 Gln/Lys(CAA/AAA) 5 (12.9) 1024
Gln/Leu(CAA/CTA) 4 (10.3) 512 Gln/Leu(CAA/CTA) 2 (5.1) 512
Gln/Arg(TCA/TTA) 1 (2.6) 512
471 14 (35.9)
Asp/Asn(GAC/AAC) 4 (10.3) <1
Asp/Glu(GAC/GAG) 1 (2.6) <1
Asp/Gly(GAC/GGC) 3 (7.7) <1
Asp/Val(GAC/GTC) 1 (2.6) 32
Asp/Tyr(GAC/TAC) 4 (10.3) 32
Asp/Cys(GAC/TGC) 1 (2.6) <1
474 1 (2.6)
Asn/Lys(AAC/AAG) 1 (2.6) 8
477 12 (30.8) 477 12 (30.8)
Ala/Asp(GCT/GAT) 7 (17.9) 512 Ala/Asp(GCT/GAT) 12 (30.8) 512
Ala/Val(GCT/GTT) 6 (15.4) 2
481 17 (43.6) 481 33 (84.6)
His/Tyr(CAT/TAT) 13 (41.9) 1024 His/Tyr(CAT/TAT) 31 (79.5) 1024
His/Leu(CAT/CTT) 3 (7.7) 256 His/Leu(CAT/CTT) 4 (10.3) 256
His/Asp(CAT/GAT) 2 (5.1) 1024 His/Asp(CAT/GAT) 4 (10.3) 1024
His/Asn(CAT/AAT) 3 (7.7) 512
484 13 (33.3) 484 7 (17.9)
Arg/His(CGT/CAT) 11 (28.2) 256 Arg/His(CGT/CAT) 7 (17.9) 512
Arg/Ser(CGT/AGT) 2 (5.1) 64
Arg/Cys(CGT/TGT) 1 (2.6) 16
486 3 (7.7) 486 13 (33.3)







Pro/Leu(CCT/CTT) 1 (2.6) <1
527 3 (7.7)
Ile/Phe(ATT/TTT) 3 (7.7) 32
529 1 (2.6)
Ser/Leu(TCA/TTA) 1 (2.6) 256
400 H.-J. Tang et al.greater potential for the induction of rifampin resistance in
the biofilm. As for the mutation in codon 474 (AAC/AAT),
which is rarely mentioned in the literature, we noted it in
w60% of our MRSA isolates. Its significance is unknown and
needs further evaluation.
In conclusion, we documented a high induction potential
of rifampin resistance when MRSA was engaged in the bio-
film with rifampin exposure. Therefore, rifampin mono-
therapy is inadequate for MRSA in biofilm. Development of
combination regimens with minimal rifampin resistance
inducing potential for MRSA in biofilms is warranted.Conflicts of interests
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